vs
Side-by-side financial comparison of Krystal Biotech, Inc. (KRYS) and QIAGEN N.V. (QGEN). Click either name above to swap in a different company.
Krystal Biotech, Inc. is a clinical-stage biotechnology company specializing in the research, development and commercialization of novel gene therapies for rare, serious dermatological diseases with high unmet medical needs. It primarily serves patients across North America and Europe, focusing on monogenic skin disorders that lack effective standard treatment options.
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located ...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $107.1M | — | ||
| Q3 25 | $97.8M | — | ||
| Q2 25 | $96.0M | — | ||
| Q1 25 | $88.2M | — | ||
| Q4 24 | $91.1M | — | ||
| Q3 24 | $83.8M | — | ||
| Q2 24 | $70.3M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $51.4M | — | ||
| Q3 25 | $79.4M | — | ||
| Q2 25 | $38.3M | — | ||
| Q1 25 | $35.7M | — | ||
| Q4 24 | $45.5M | — | ||
| Q3 24 | $27.2M | — | ||
| Q2 24 | $15.6M | — | ||
| Q1 24 | $932.0K | — |
| Q4 25 | 41.5% | — | ||
| Q3 25 | 42.3% | — | ||
| Q2 25 | 40.9% | — | ||
| Q1 25 | 41.0% | — | ||
| Q4 24 | 45.4% | — | ||
| Q3 24 | 26.8% | — | ||
| Q2 24 | 12.2% | — | ||
| Q1 24 | -14.8% | — |
| Q4 25 | 48.0% | — | ||
| Q3 25 | 81.2% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 40.5% | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 32.4% | — | ||
| Q2 24 | 22.2% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | $1.69 | — | ||
| Q3 25 | $2.66 | — | ||
| Q2 25 | $1.29 | — | ||
| Q1 25 | $1.20 | — | ||
| Q4 24 | $1.53 | — | ||
| Q3 24 | $0.91 | — | ||
| Q2 24 | $0.53 | — | ||
| Q1 24 | $0.03 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
